渤健Biogen (BIIB) 2020年年度报告「NASDAQ」.pdf

《渤健Biogen (BIIB) 2020年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen (BIIB) 2020年年度报告「NASDAQ」.pdf（198页珍藏版）》请在三个皮匠报告上搜索。

1、Annual ReportBiogen ANNUAL REPORT 2020 CONTAINSSOYOIL20162017201820192020$13,445$14,378$13,453$12,274$11,449201620172018201920202016201720182019202020162017201820192020$16.93$20.22$11.92 3$22.72 2$21.58 3$27.44 2$31.42$33.57$6,564$13,445$24.80$33.70 2$3,805$14,378$13,453$5,417$12,274$3,684$11,449$3,

2、90620162017201820192020$6,564$3,805$5,417$3,684$3,906Fumarate 5Interferon 6TYSABRISPINRAZAOther 7$3,905 36.5%$4,438 39.0%$1,878 17.6%$2,102 18.5%$1,946 18.2%$1,892 16.6%$2,052 19.2%$2,097 18.4%$911 8.5%$851 7.5%Product Revenue by Region(%of total product revenue)55%45%59%41%63%37%Free cash flow 1,4(

3、$inmillions)Total Revenue($inmillions)GAAP Diluted EPS Non-GAAP Diluted EPS 1Product Revenue($inmillions and%of total product revenue)1 Non-GAAP diluted earnings per share(EPS)and free cash flow are Non-GAAP financial measures.A reconciliation of GAAP to Non-GAAP diluted EPS and free cash flow amoun

4、ts is set forth on pages 1013 of this Annual Report.2 Beginning in the third quarter of 2020,material upfront payments associated with significant collaboration and licensing arrangements are excluded from Non-GAAP R&D expense in order to better reflect the Companys core operating performance.Prior

5、period Non-GAAP results have been updated to reflect this change.3 GAAP diluted EPS for 2018 and 2017 includes charges of$125million and$1,174million,respectively,related to the impact of the Tax Cuts and Jobs Act of 2017.4 Beginning in 2020,free cash flow was redefined as net cash flow from operati

6、ons less capital expenditure.Prior period free cash flow amounts have been updated to reflect this change.Free cash flow for 2016 through 2019 reflects an increase in capital expenditures related to the construction of our largescale biologics manufacturing facility in Solothurn,Switzerland.5 Fumara